CANY
SYRS

Caxton Associates (New York)’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Caxton Associates (New York)’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-6,683
Closed -$218K – 751
2021
Q4 		$218K Buy
+6,683
New +$271K 0.02% 480

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Caxton Associates (New York)'s SYRS Position: Q1 2022 in Review

Caxton Associates (New York) sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2022, closing a stake of 6,683 shares — an estimated $218K sold.

Caxton Associates (New York) first reported a position in SYRS in Q4 2021 and held it in 1 quarter. The position peaked at $218K in Q4 2021. 94 funds tracked by Wall St. Rank hold SYRS as of Q1 2022.

  • Caxton Associates (New York) reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 6,683 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2022, an estimated $218K.
  • Caxton Associates (New York) first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Caxton Associates (New York)'s Syros Pharmaceuticals, Inc. Common Stock position peaked at $218K in Q4 2021.
  • 94 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2022.

Based on Caxton Associates (New York)'s 13F filing for Q1 2022, filed 16 May 2022.